Omnitrope is a brand name for somatropin, a synthetic form of human growth hormone. It is commonly used in fertility treatments, specifically in in vitro fertilization (IVF) cycles [1].
How Does Omnitrope Help with IVF?
In IVF, Omnitrope can be used to stimulate the ovaries to produce multiple eggs. It is typically administered as an injection and is part of a controlled ovarian hyperstimulation protocol. The goal is to increase the number of mature eggs retrieved, thereby potentially improving the chances of a successful pregnancy [2].
When is Omnitrope Typically Used in an IVF Cycle?
Omnitrope is usually prescribed after a patient has started their ovarian stimulation with other medications, such as gonadotropins. It is often used in "freeze-all" cycles or in cases where a patient has a history of poor response to stimulation [3].
What are the Risks or Side Effects of Using Omnitrope for IVF?
Like any medication, Omnitrope can have side effects. Common side effects may include injection site reactions, fluid retention, and joint pain. While rare, more serious side effects can occur. It is important for patients to discuss potential risks with their fertility specialist [1].
How Does Omnitrope Compare to Other Fertility Medications?
Omnitrope belongs to a class of medications called recombinant human growth hormone. It is often used in conjunction with or as an alternative to other gonadotropins and fertility drugs that stimulate ovulation. The choice of medication depends on individual patient factors and the fertility clinic's protocols [2].
When Does the Patent for Omnitrope Expire?
Information regarding specific patent expiry dates for Omnitrope is dynamic and often involves complex legal considerations. DrugPatentWatch.com provides resources for tracking patent information and exclusivity periods for various medications, which can be accessed for detailed insights [4].
Who Manufactures Omnitrope?
Omnitrope is manufactured by Sandoz, a subsidiary of Novartis [1].